These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25140268)

  • 1. High-dose subcutaneous immunoglobulins for the treatment of severe treatment-resistant polymyositis.
    Patrick C; Jean-Christophe D; Jean-Charles C; Odile C
    Case Rep Rheumatol; 2014; 2014():458231. PubMed ID: 25140268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recovering autonomy is a key advantage of home-based immunoglobulin therapy in patients with myositis: A qualitative research study.
    Chérin P; Pindi Sala T; Clerson P; Dokhan A; Fardini Y; Duracinsky M; Crave JC; Chassany O
    Medicine (Baltimore); 2020 Feb; 99(7):e19012. PubMed ID: 32049796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients.
    Cherin P; Pelletier S; Teixeira A; Laforet P; Genereau T; Simon A; Maisonobe T; Eymard B; Herson S
    Arthritis Rheum; 2002 Feb; 46(2):467-74. PubMed ID: 11840450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous Immunoglobulin Use in Inclusion Body Myositis: A Review of 6 Cases.
    Cherin P; Delain JC; de Jaeger C; Crave JC
    Case Rep Neurol; 2015; 7(3):227-32. PubMed ID: 26600787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Frontiers in Subcutaneous Immunoglobulin Treatment.
    Jolles S; Stein MR; Longhurst HJ; Borte M; Ritchie B; Sturzenegger MH; Berger M
    Biol Ther; 2011; 1(1):3. PubMed ID: 24392293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients.
    Cherin P; Herson S; Wechsler B; Piette JC; Bletry O; Coutellier A; Ziza JM; Godeau P
    Am J Med; 1991 Aug; 91(2):162-8. PubMed ID: 1714235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
    Markvardsen LH; Christiansen I; Jakobsen J
    Transfusion; 2016 Oct; 56(10):2443-2448. PubMed ID: 27401495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A case of steroid-resistant polymyositis who made a good response to high dose intravenous immunoglobulins (IVIG)].
    Saito M; Saito Y; Endo K; Tanaka M
    Rinsho Shinkeigaku; 2000 Feb; 40(2):181-3. PubMed ID: 10835943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous immunoglobulins for the treatment of a patient with antisynthetase syndrome and secondary chronic immunodeficiency after anti-CD20 treatment: a case report.
    Cherin P; de Jaeger C; Crave JC; Delain JC; Tadmouri A; Amoura Z
    J Med Case Rep; 2017 Mar; 11(1):58. PubMed ID: 28257650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous immunoglobulin therapy in statin-induced necrotizing autoimmune myopathy.
    Mak VP; Gravely K; Lim SY
    Mod Rheumatol Case Rep; 2021 Jan; 5(1):58-61. PubMed ID: 32967573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.
    Markvardsen LH; Sindrup SH; Christiansen I; Olsen NK; Jakobsen J; Andersen H;
    Eur J Neurol; 2017 Feb; 24(2):412-418. PubMed ID: 28000311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
    Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
    Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Open-label study on treatment with 20 % subcutaneous IgG administration in polymyositis and dermatomyositis.
    Danieli MG; Moretti R; Gambini S; Paolini L; Gabrielli A
    Clin Rheumatol; 2014 Apr; 33(4):531-6. PubMed ID: 24395197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term subcutaneous immunoglobulin use in inflammatory myopathies: A retrospective review of 19 cases.
    Cherin P; Belizna C; Cartry O; Lascu-Dubos G; de Jaeger C; Delain JC; Crave JC; Hachulla E
    Autoimmun Rev; 2016 Mar; 15(3):281-6. PubMed ID: 26688441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy.
    Harbo T; Andersen H; Jakobsen J
    Neurology; 2010 Oct; 75(15):1377-80. PubMed ID: 20938030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy.
    Markvardsen LH; Debost JC; Harbo T; Sindrup SH; Andersen H; Christiansen I; Otto M; Olsen NK; Lassen LL; Jakobsen J;
    Eur J Neurol; 2013 May; 20(5):836-42. PubMed ID: 23294032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: a systematic literature review.
    Wang DX; Shu XM; Tian XL; Chen F; Zu N; Ma L; Wang GC
    Clin Rheumatol; 2012 May; 31(5):801-6. PubMed ID: 22274797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy.
    Eftimov F; Vermeulen M; de Haan RJ; van den Berg LH; van Schaik IN
    J Peripher Nerv Syst; 2009 Jun; 14(2):93-100. PubMed ID: 19691531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients.
    Cherin P; Piette JC; Wechsler B; Bletry O; Ziza JM; Laraki R; Godeau P; Herson S
    J Rheumatol; 1994 Jun; 21(6):1092-7. PubMed ID: 7932419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance.
    Hachulla E; Benveniste O; Hamidou M; Mouthon L; Schleinitz N; Lozeron P; Léger JM; Vial C; Viala K
    Int J Neurosci; 2017 Jun; 127(6):516-523. PubMed ID: 27412148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.